Correlation Engine 2.0
Clear Search sequence regions

  • antibiotics (1)
  • humans (1)
  • immunosuppressants (1)
  • liver (2)
  • lung (1)
  • organ (9)
  • pancreas (1)
  • patients (3)
  • Sizes of these terms reflect their relevance to your search.

    The increasing occurrence of multidrug-resistant organisms (MDROs) infections has posed major challenge to solid organ transplantation (SOT). For SOT recipients, high-dose immunosuppressants and broad-spectrum antibiotics can markedly increase the risk of early postoperative MDRO infections and thus have adverse effects on the outcomes of SOT. Here, we analyzed the incidence and clinical features of early MDRO infections after SOT, in an attempt to provide new evidence for the control and treatment of early MDROs. The clinical data of 133 patients with MDRO infections after SOT in our department from 2017 to 2020 were retrospectively collected, and clinical features including incidence, etiologies, infection sites, and complications, were analyzed. The incidence of MDRO infections after SOT was 9.9%. Simultaneous liver and kidney transplantation patients had the highest incidence of MDRO infections, followed by the recipients of liver transplantation and simultaneous pancreas-kidney transplantation; patients undergoing renal transplantation had the lowest incidence of MDRO infections. The most common pathogen was extended spectrum beta-lactamase (ESBL)-producing organisms (n=88, 66.2%), the most common infection site was the urinary system (n=58, 43.6%), and the main postoperative complications were urinary tract infections (n=44, 33.1%) and lung infections (n=41, 30.8%). MDRO infections were cured in most cases. A sound knowledge of the clinical features of MDRO infection after SOT is important for the successful prevention and treatment of these infections.


    Min Jin, Lijuan Zeng, Wanyi Zhang, Xuanying Deng, Jiali Li, Weiting Zhang. Clinical features of multidrug-resistant organism infections in early postoperative solid organ transplantation in a single center. Annals of palliative medicine. 2021 Apr;10(4):4555-4562

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 33966403

    View Full Text